Printer Friendly

NOVO NORDISK A/S HOLDS ANNUAL GENERAL MEETING

 NOVO NORDISK A/S HOLDS ANNUAL GENERAL MEETING
 BAGSVAERD, Denmark, April 29 /PRNewswire/ -- At the annual general


meeting of Novo Nordisk A/S (NYSE: NVO) today, shareholders approved the proposals made by the board of directors. The main items were:
 -- Payment of a cash dividend of 20 percent of the nominal share value or DKK 4 per share (and per ADS).
 -- Re-election of the following to the board of directors: Palle Marcus; Allan Philip; Jaromir Ruzicka; Hans Werdelin; and Mads Ovlisen.
 -- Re-election of the auditors Price Waterhouse/Seier-Petersen and Ernst & Young A/S represented by John Lundin, CPA.
 -- Authorization for the board of directors to issue - in one or more stages - up to a total of DKK 25 million nominal value of B shares as employee shares.
 At the annual general meeting, Vagn Andersen, chairman of the board of directors, expressed his satisfaction with Novo Nordisk's results which show continued and significant progress at a time characterized by recession in many countries. In 1991, Novo Nordisk had a net turnover of DKK 9.4 billion and a net income of DKK 928 million. THe company's exports amounted to approximately DKK 7 billion thus accounting for around 4 percent of Denmark's total industrial exports.
 Maintain A and B shares
 Vagn Andersen told the shareholders that in connection with the share capital increase in 1991, the Novo Nordisk Foundation - which owns all A shares of the company - purchased new shares in Novo Nordisk A/S amounting to DKK 331 million net in order to retain its relative ownership share of the company. The foundation has thus applied approximately ten years' accumulated profit.
 "The foundation has thus contributed significantly to the continued efforts to retain Novo Nordisk as a stable and dynamic place of work in which people find it attractive to invest work and capital," commented Vagn Anderson. "The Novo Nordisk Foundation as well as the board of directors and corporate management board of Novo Nordisk A/S are therefore pleased with the recommendation by the Company Law Panel of the Danish Ministry of Industry to maintain the present Danish rules for differentiated voting power of A and B shares. If these rules cannot be upheld, transitional stipulations should be established for existing companies so as to ensure that no changes will be made for shares already issued. We hope that the Minister of Industry and the government will maintain this attitude," said Vagn Andersen.
 Danish Membership of European Union to Benefit Novo Nordisk
 Commenting on the upcoming June 2 Danish Referendum on the European Union, the chairman said that he believed that Danish membership of the European Union would be extremely beneficial for Novo Nordisk and Danish industry as a whole.
 "This is the only way to ensure that Danish industry obtains the best possible terms of competition and a central position in the continuously expanding European research collaboration, for the benefit of the Danish as well as the European society," Andersen said.
 Board of Directors
 At a board meeting held immediately after the general meeting, the board of directors elected Vagn Anderson chairman. The board of directors henceforth consists of the following:
 Vagn Andersen (chairman)
 Hanne B. Fabricius, production chemist (employee representative)
 Olav Haugan, electrician (employee representative)
 Flemming Junker, senior chemist (employee representative)
 Preben Kristensen, fitter (employee representative)
 Jette Lundgren, medical laboratory technician (employee representative)
 Palle Marcus, president, Danisco A/S
 Allan Philip, partner, Pontoppidan, Philip & Partners
 Jaromir Ruzicka, professor, University of Washington
 Ole Scherfig, director
 Hans Werdelin, president, Sophus Berendsen A/S
 Mads Ovlisen, president, Novo Nordisk, A/S
 Novo Nordisk A/S is a major force in insulin production and diabetes care and is the world's largest producer of industrial enzymes. The company also manufactures and markets a variety of other pharmaceutical and bioindustrial products. Headquartered in Denmark, Novo Nordisk employs more than 10,000 people in over 40 countries aNd markets its products in 130 countries. Its B shares are listed on the stock exchanges in Copenhagen, London, Basel, Zurich and Geneva.
 -0- 4/29/92
 /CONTACT: Margaret Jo Ringsted of Novo Nordisk of North America, 212-867-0123, or Leonard Ellis of Fleishman-Hillard, Inc., 212-265-9150, for Novo Nordisk of North America/
 (NVO) CO: Novo Nordisk A/S ST: IN: MTC SU:


PS-AH -- NY084 -- 4636 04/29/92 17:50 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 29, 1992
Words:712
Previous Article:ORANGE-CO ANNOUNCES THE ACQUISITION OF 52.3 PERCENT OF ITS STOCK BY BEN HILL GRIFFIN, INC. AND BEN HILL GRIFFIN III OF FROSTPROOF, FLA.
Next Article:PIONEERING VIDEO COMPANY LAUNCHED TARGETING TRADITIONAL FAMILY VALUES MARKET


Related Articles
ANNUAL GENERAL MEETING AT NOVO NORDISK A/S
Annual General Meeting at Novo Nordisk A/S
Annual General Meeting at Novo Nordisk A/S
Annual General Meeting at Novo Nordisk A/S.
The Demerger of Novo Nordisk Moving One Step Closer.
Demerger of Novo Nordisk A/S (NYSE: NVO) Approved at Extraordinary General Meeting.
Annual General Meeting at Novo Nordisk A/S.
Sten Scheibye Proposed as New Member of Novo Nordisk's Board of Directors.
Annual General Meeting at Novo Nordisk A/S.
Novo Nordisk A/S - AGM Statement.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters